

UnitedHealthcare Community Plan Medical Policy Update Bulletin: May 2024

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

Medical Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|----------------|
| Breast Reduction Surgery | Updated | Jul. 1, 2024 |
| Breast Reduction Surgery (for New Jersey Only) | Updated | Jul. 1, 2024 |
| Cardiac Event Monitoring | Revised | Jul. 1, 2024 |
| Cardiovascular Disease Risk Tests (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Chemotherapy Observation or Inpatient Hospitalization | Revised | Jul. 1, 2024 |
| Chemotherapy Observation or Inpatient Hospitalization (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Electrical Bioimpedance for Cardiac Output Measurement | Retired | May 1, 2024 |
| Enteral Nutrition (Oral and Tube Feeding) | Updated | May 1, 2024 |
| Enteral Nutrition (Oral and Tube Feeding) (for New Jersey Only) | Updated | May 1, 2024 |
| Genetic Testing for Neuromuscular Disorders (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Home Health, Skilled, and Custodial Care Services (for New Jersey Only) | Updated | May 1, 2024 |
| Laser Interstitial Thermal Therapy | Retired | May 1, 2024 |
| Laser Interstitial Thermal Therapy (for New Jersey Only) | Retired | May 1, 2024 |
| Mobility Devices, Options, and Accessories | Updated | May 1, 2024 |
| Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions | Revised | Jul. 1, 2024 |
| Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions (for Nebraska Only) | Updated | Jul. 1, 2024 |
| Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Omnibus Codes | Revised | Jul. 1, 2024 |
| Omnibus Codes (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Omnibus Codes (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Orthognathic (Jaw) Surgery | Revised | Jul. 1, 2024 |
| Orthognathic (Jaw) Surgery (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Orthognathic (Jaw) Surgery (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Pediatric Gait Trainers and Standing Systems (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Preimplantation Genetic Testing and Related Services | Revised | Jul. 1, 2024 |
| Preimplantation Genetic Testing and Related Services (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Preimplantation Genetic Testing and Related Services (for New Jersey Only) | Revised | Jul. 1, 2024 |

| Policy Title | Status | Effective Date |
|--|---------|----------------|
| Prostate Surgeries and Interventions | Revised | Jul. 1, 2024 |
| Prostate Surgeries and Interventions (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Rhinoplasty and Other Nasal Procedures | Revised | Jul. 1, 2024 |
| Rhinoplasty and Other Nasal Procedures (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Rhinoplasty and Other Nasal Procedures (for New Jersey Only) | Revised | Jul. 1, 2024 |
| Skin and Soft Tissue Substitutes (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Speech Generating Devices | Updated | May 1, 2024 |
| Transanal Minimally Invasive Surgical Procedures (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Walkers | Revised | Jul. 1, 2024 |
| Walkers (for Nebraska Only) | Revised | Jul. 1, 2024 |
| Walkers (for New Jersey Only) | Revised | Jul. 1, 2024 |

Coverage Determination Guideline Updates

| Policy Title | Status | Effective Date |
|--|----------|----------------|
| Speech Language Pathology Services (for New Jersey Only) | Replaced | Jun. 1, 2024 |

Medical Benefit Drug Policy Updates

| Policy Title | Status | Effective Date |
|--|---------|----------------|
| Adzynma (ADAMTS13, Recombinant-Krhn) | Updated | May 1, 2024 |
| Cosentyx® (Secukinumab) | New | Jun. 1, 2024 |
| Entyvio® (Vedolizumab) | Revised | Jun. 1, 2024 |
| Erythropoiesis-Stimulating Agents | Updated | Jun. 1, 2024 |
| Evenity® (Romosozumab-Aqqg) | Updated | Jun. 1, 2024 |
| Ilumya® (Tildrakizumab-Asmn) | Revised | Jun. 1, 2024 |
| Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) | Updated | Jun. 1, 2024 |
| Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) | Revised | Jun. 1, 2024 |
| Ketalar® (Ketamine) and Spravato® (Esketamine) | Revised | Jun. 1, 2024 |
| Ketalar® (Ketamine) and Spravato® (Esketamine) (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Maximum Dosage and Frequency | Revised | Jun. 1, 2024 |
| Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease | Revised | Jun. 1, 2024 |
| Oncology Medication Clinical Coverage | Revised | Jun. 1, 2024 |
| Oxlumo® (Lumasiran) and Rivfloza™ (Nedosiran) | Revised | Jun. 1, 2024 |
| Qalsody® (Tofersen) | Revised | Jun. 1, 2024 |
| Respiratory Interleukins (Cinqair°, Fasenra°, & Nucala°) | Updated | May 1, 2024 |
| Rituximab (Riabni [®] , Rituxan [®] , Ruxience [®] , & Truxima [®]) | Revised | Jun. 1, 2024 |
| Ryplazim® (Plasminogen, Human-Tvmh) | Updated | Jun. 1, 2024 |
| Saphnelo® (Anifrolumab-Fnia) | Updated | Jun. 1, 2024 |
| Simponi Aria® (Golimumab) Injection for Intravenous Infusion | Updated | May 1, 2024 |
| Tezspire® (Tezepelumab-Ekko) | Updated | Jun. 1, 2024 |
| Uplizna® (Inebilizumab-Cdon) | Revised | Jun. 1, 2024 |
| Veopoz [™] (Pozelimab-Bbfg) | Revised | Jun. 1, 2024 |
| Viltepso® (Viltolarsen) | Revised | Jun. 1, 2024 |

| Policy Title | Status | Effective Date |
|---|---------|-------------------------|
| Viltepso® (Viltolarsen) (for New Jersey Only) | Revised | Jun. 1, 2024 |
| Vyepti® (Eptinezumab-Jjmr) | Revised | Jun. 1, 2024 |
| Xolair® (Omalizumab) | Revised | Jun. 1, 2024 |
| Updated May 13, 2024 : Implementation of revisions to this policy has been postponed until further notice. | | |

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan Medical Policies and Medical Benefit Drug Policies is available at **UHCprovider.com** > Policies and Protocols > Community Plan Policies > Medical & Drug Policies.